Stockpolly
Search
MCRB · NASDAQ · Biotechnology

Seres Therapeutics (MCRB)

Develops oral bacterial consortia for infection, immune, and inflammatory conditions.

$5.54
Pre-market+0.03 (+0.54%)
At close$5.51(+6.37%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000001
Cost of revenue00190154113−1410
Gross profit00−190−1−5−4−1−131401
45401529282424249342022
Research & development25271916161312131312139
19171513111212109887
General & administrative1917151301212109887
Other expenses0−4−1900−201−1314−16
Operating income−45−40−34−29−29−29−27−25−22−19−21−21
4−223−2213605314126
Interest income322110111000
Interest expense445300000000
Other non-operating income−4−2−2−322−13−60−5−31−4−10
Income before tax−41−41−33−26−51−1633−208−15−205
Net income from continuing operations−41−41−33−26−51−1633−208−15−205
Discontinued operations−70−7−71400000000
Net income−48−41−40−3389−1633−208−15−205
EPS, basic−$7.46−$6.38−$5.49−$4.34−$7.59−$1.81$3.76−$2.27$0.94−$1.77−$2.08$0.49
EPS, diluted−$7.46−$6.38−$5.49−$4.34−$7.59−$1.81$3.75−$2.27$0.94−$1.76−$2.08$0.49
Weighted average shares, basic66788999991010
Weighted average shares, diluted66788999991010
EBITDA−39−36−31−25−50−1534−199−13−19−21
Depreciation & amortization222111111210
EBIT−41−37−32−26−51−1633−208−15−20−21